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Abstract
Background: Pulmonary hypertension and left ventricular diastolic dysfunction are complications of sickle cell disease.
Pulmonary hypertension is associated with hemolysis and hypoxia, but other unidentified factors are likely involved in
pathogenesis as well.
Design and Methods: Plasma concentrations of three angiogenic markers (fibroblast growth factor, platelet derived growth
factor–BB [PDGF-BB], vascular endothelial growth factor [VEGF]) and seven inflammatory markers implicated in pulmonary
hypertension in other settings were determined by Bio-Plex suspension array in 237 children and adolescents with sickle cell
disease at steady state and 43 controls. Tricuspid regurgitation velocity (which reflects systolic pulmonary artery pressure),
mitral valve E/Edti ratio (which reflects left ventricular diastolic dysfunction), and a hemolytic component derived from four
markers of hemolysis and hemoglobin oxygen saturation were also determined.
Results: Plasma concentrations of interleukin-8, interleukin-10 and VEGF were elevated in the patients with sickle cell
disease compared to controls (P#0.003). By logistic regression, greater values for PDGF-BB (P=0.009), interleukin-6
(P=0.019) and the hemolytic component (P=0.026) were independently associated with increased odds of elevated
tricuspid regurgitation velocity while higher VEGF concentrations were associated with decreased odds (P=0.005) among
the patients with sickle cell disease. These findings, which are consistent with reports that PDGF-BB stimulates and VEGF
inhibits vascular smooth muscle cell proliferation, did not apply to E/Etdi.
Conclusions: Circulating concentrations of angiogenic and pro-Inflammatory markers are altered in sickle cell disease
children and adolescents with elevated tricuspid regurgitation velocity, a subgroup that may be at risk for developing
worsening pulmonary hypertension. Further studies to understand the molecular changes in these children are indicated.
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Introduction
Pulmonary hypertension and left ventricular diastolic dysfunction
are found in up to 32% and 18% of adults with sickle cell disease,
respectively, and are associated with reduced exercise tolerance and
high mortality [1,2,3]. Elevated estimated systolic pulmonary artery
pressures [4,5,6] and left ventricular stiffness [7] are recognized to
d e v e l o pi nc h i l d r e nw i t hs i c k l ec e l ld isease but the clinical importance
is not clear [7,8]. Echocardiography can be employed to non-
invasively estimate systolic pulmonary artery pressure and left
ventricular diastolic function. Tricuspid regurgitation velocity reflects
systolic pulmonary artery pressure [1] and the ratio of early diastolic
mitral inflow velocity to early diastolic tissue Doppler imaging annular
velocity (E/Etdi) reflects left ventricular diastolic function [9,10].
The Pulmonary Hypertension and Hypoxic Response in
Sickle Cell Disease (PUSH) Study is an on-going multicenter
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7956observational study that was designed to identify factors in pre-
symptomatic children with sickle cell disease that are predictors
of cardiopulmonary complications and that therefore are
potential mechanistic targets for early preventive intervention.
Using a conservative definition of $2.6 m/sec, we recently
reported that 11% of 310 children and adolescents with sickle
cell disease had elevated tricuspid regurgitation velocity at steady
state and that elevated velocity had independent associations
with degree of hemolysis and with lower hemoglobin oxygen
saturation [6]. We also reported that 5% had elevated E/Etdi
[6]. Although a functional deficit was not found in the children
with elevated tricuspid regurgitation velocity as measured by the
six-minute walk test, there was a statistically significant decrease
in oxygenation during the test. This observation indicates that
the children with elevation of tricuspid regurgitation velocity are
biologically different with respect to pulmonary vascular
function compared to those with lower velocities. Thus, albeit
pending the results of long term studies, elevated tricuspid
regurgitation velocity may be an early marker of disease that
identifies a subset of sickle cell disease patients at risk for
developing pulmonary hypertension later in life and that could
be used to discover the early underlying mechanisms of
pulmonary hypertension.
The factors that lead to the development of cardiopulmonary
complications in the setting of sickle cell disease have not been
fully identified. Studies in both adults [1] and children [5,6]
with sickle cell disease have found correlations between
hemolysis and pulmonary hypertension. Intravascular hemolysis
contributes to a hemolytic vasculopathy in part through
scavenging nitric oxide, a key modulator of microvascular
function [11], and through limiting availability of arginine, the
s u b s t r a t ef o rn i t r i co x i d es y n t h a s e[ 1 2 ] .H e m o l y s i sd o e sn o tf u l l y
explain the finding of pulmonary hypertension in this setting,
for pulmonary hypertension develops in patients with hemoglo-
bin SC or Sb+-thalassemia, conditions with markedly less
hemolysis than hemoglobin SS [1,13]. In addition and possibly
related to the hemolytic process, h y p o x i am a yb eac o n t r i b u t i n g
factor [6]. Humans exposed to chronic hypoxia have a tendency
to develop pulmonary hypertension [14], and patients with
sickle cell disease may experience hypoxia due to anemia,
chronic hemoglobin oxygen desaturation, upper airway ob-
struction and repeated episodes of vasoocclusive pain crisis and/
or acute chest syndrome [15,16,17,18,19,20]. Hypercoagulabil-
ity [21], platelet activation [22] and up-regulation of the
inflammatory response [21] have also been proposed as
contributing to the development of pulmonary hypertension in
sickle cell disease. Although a number of biological pathways
have been implicated in sickle cell disease, few molecular targets
have been identified.
Altered expression of inflammatory molecules and angiogenic
growth factors have been observed in primary pulmonary
hypertension and/or non-sickle cell disease-related forms of
secondary pulmonary hypertension. These markers include
interleukin-6 [23,24], interleukin-8 [25], interleukin-10 [26],
tumor necrosis factor-a [27], monocyte chemoattractant protein-
1 [25], RANTES [28], vascular endothelial growth factor (VEGF)
[29], platelet-derived growth factor (PDGF) [30] and fibroblast
growth factor [31]. Likewise, increased exposure to inflammatory
cytokines such as interleukin-6 and tumor necrosis factor-a [32,33]
and angiogenic factors such as PDGF and VEGF [34,35] has been
associated with altered cardiac function in settings other than
sickle cell disease. Our hypothesis is that inflammatory and
angiogenic factors contribute to the pathogenesis of cardiopulmo-
nary complications in sickle cell disease. We therefore measured
circulating concentrations of inflammatory and angiogenic
markers and correlated them with cardiopulmonary findings in a
subgroup of children and adolescents with sickle cell disease
enrolled in the PUSH Study.
Methods
Study Participants
This report includes a subset of children and adolescents with
sickle cell disease from 3 to 20 years of age and control participants
who were evaluated at steady state as previously described [6].
Controls were matched by age, sex and ethnicity to every sixth
patient with sickle cell disease enrolled in the study and included
individuals with hemoglobin AA, hemoglobin AS or hemoglobin
AC. This report includes 237 patients and 43 controls who were
enrolled in the study as of early 2008. Patients had hemoglobin SS,
SC, Sb-thalassemia or other major sickling phenotypes as
determined by hemoglobin electrophoresis or HPLC and
confirmed by molecular genetic testing (see below). Hemoglobins
S and C are mutated forms of hemoglobin while hemoglobin A is
the normal form. b-thalassemia refers to mutations in which there
is reduced or absent production of b-globin. Two copies of
mutated forms indicate hemolytic anemia such as hemoglobin SS
disease (sickle cell anemia), hemoglobin SC disease or sickle-b-
thalassemia. Patients had to be at least three weeks out from
hospitalization or emergency room visit for acute pain, vasoocclu-
sion or infection and controls had to be at least three weeks out
from acute infections or other illnesses. Participants were recruited
at three centers: Howard University and Children’s National
Medical Center in Washington, DC and the University of
Michigan in Ann Arbor, Michigan. The research was approved
by the IRBs of each participating institution and written consent
was obtained for all participants. Hemoglobin oxygen saturation
was measured by pulse oximetry. Reticulocyte count, lactate
dehydrogenase, aspartate aminotransaminase and total bilirubin
were analyzed by automated methodology at each institution and
used to develop the hemolytic component described in the
Statistical analysis section below. Among the patients with sickle
cell disease 11 (4.7%) had mitral valve E/Etdi $9.22, 46 (21.1%)
had tricuspid regurgitation velocity $2.5 m/sec, and 21 (9.6%)
had regurgitation velocity $2.6 m/sec. Tricuspid regurgitation
velocity elevations of this magnitude predict only mild elevations in
systolic pulmonary artery pressure and their functional significance
has not been determined in children and adolescents with sickle
cell disease. Among adults with sickle cell disease, such elevations
are associated with high mortality during two years of follow-up
[1].
Molecular Genetic Testing
Hemoglobin S, C genotyping was conducted at ARUP
Laboratories (Salt Lake City, UT) using loci-spanning probe –
PCR as described[36]. Genotyping was performed using the
LightCycler480 (LC480) Real-Time PCR System (Roche Applied
Science, Indianapolis, IN) using 100 ng DNA, 5 mL LightCycler
480 Probes Master (2x) mix (Roche Applied Sciences), 0.2 nM
PCR primers, 0.5 nM LSProbes (Idaho Technology, Salt Lake
City, UT) in a 10 mL PCR reaction. Cycling parameters were
modified from those previously described for the LC480 System.
The LC480 parameters were: denaturation at 94uC for 10
minutes, followed by 40 cycles of 95uC for 10 seconds, 63uC for
1 minute, and 75uC for 5 seconds. Loci-spanning probe melt
analysis was preformed by continuous signal acquisition between
38uC–6 5 uC at default ramp rate of 0.6uC/s and 5 acquisitions
per uC.
Biologic Markers in SCD
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Plasmaconcentrationsoftenbiological markers wereassayed ina
subgroup of patients and controls using the Bio-Plex suspension
array system (Bio-Rad, Hercules, CA): interleukins-6, 8 and 10,
interferon-c, tumor necrosis factor-a, monocyte chemoattractant
protein-1, basic fibroblast growth factor, PDGF (platelet-derived
growth factor)-BB, VEGF (vascular endothelial growth factor) and
RANTES (Regulated upon Activation, Normal T-cell Expressed,
and Secreted). The system allows simultaneous identification of
cytokines in a 96 well filter plate. In brief, the appropriate cytokine
standardsandsamplesdiluted inplasmadiluents wereadded toa 96
well filter plate. The samples were incubated at room temperature
for 30 minutes with antibodies chemically attached to fluorescent-
labeled micro beads. After three filter washes, premixed detection
antibodies were added to each well and incubated for 30 min.
Following three washes, premixed streptavidin-phycoerythrin was
added to each well and incubated for 10 minutes followed by three
more washes. Then beads were re-suspended with 125 ml of assay
buffer and the reaction mixture was quantified using the Bio-Plex
protein array reader. Data were automatically processed and
analyzed by Bio-Plex Manager Software 4.1 using the standard
curve produced from recombinant cytokine standard.
Echocardiographic Measurements of Cardiopulmonary
Status
Doppler echocardiography was employed to estimate systolic
pulmonary artery pressure through measurement of the tricuspid
regurgitation velocity and to evaluate left ventricular diastolic
function by determining the mitral valve E/Etdi ratio as previously
described [6]. Transthoracic echocardiography was performed
using the Philips Sono 5500/7500 or iE33, Acuson Sequoia, or
General Electric VIVID 7 or VIVID I instruments. Cardiac
images were obtained, measurements performed, and studies
interpreted centrally according to guidelines of the American
Society of Echocardiography. The tricuspid regurgitation velocity
was measurable in 92% of the patients studied, and patients with
unmeasurable velocity were excluded from analyses that involved
the velocity. Based on the mean +2SD in controls, an elevated
tricuspid regurgitation velocity of $2.60 m/sec and a mitral valve
E/Etdi ratio of $9.22 were considered to be elevated.
Statistical Analysis
For continuous variables that did not follow a normal
distribution, the best transformation to a normal distribution was
made for statistical analyses. Principal component was used to
derive a hemolytic component from reticulocyte count, lactate
dehydrogenase, aspartate transaminase and bilirubin. Principal
component analysis produces a number of components equal to
the number of variables in the analysis; each component
represents a normalized standard distribution with a mean value
of 0. Continuous variables were compared between two groups
with the student t-test or with analysis of variance. Relationships
among continuous variables were determined by bivariate linear
regression. Independent associations of tricuspid regurgitation
velocity of 2.60 m/sec or higher and mitral valve E/Etdi of 9.22 or
higher with hemolytic component, hemoglobin oxygen saturation
and biologic markers were assessed by logistic regression. The
most parsimonious models were developed that included only
variables with P,0.05 in the final model. Models were checked for
model assumption and fitness. Analyses were performed with
STATA 10 (StataCorp, College Station, TX). AMOS 17.0
software (SPSS, Chicago, IL) was used to develop a mechanistic
pathway analysis model of tricuspid regurgitation velocity based
on factors that were significant, independent predictors of elevated
tricuspid regurgitation velocity by logistic regression. The final
pathway model included only parameters and relationships that
were statistically significant (P,0.05). The effect of each
relationship was presented with a standardized coefficient.
Results
Biologic Markers in Sickle Cell Disease Patients and
Controls
The median age of the 237 patients with sickle cell disease was
12 years and 46% were males. The median age of the 43 controls
was 13 years and 51% were males. Seventy-five percent of the
patients had the severe sickling genotypes of hemoglobin SS
(n=174), hemoglobin Sb
0-thalassemia (n=3) or hemoglobin
SD
LA (n=1), 38% were receiving hydroxyurea and 13% were
on a chronic transfusion program. The median tricuspid
regurgitation velocity was 2.3 m/sec in patients compared to
2.1 m/sec in controls (P=0.0004 by the student t-test). The
median mitral valve E/Etdi ratio was 6.4 in patients compared to
6.3 in controls (P=0.5). After adjustment for hydroxyurea therapy
by analysis of variance, patients with sickle cell disease had higher
plasma interleukin-8, interleukin-10, and VEGF concentrations
compared to the control participants and lower plasma RANTES
concentrations (Table 1). Concentrations of tumor necrosis factor-
a, interferon-c, VEGF and fibroblast growth factor were
significantly higher in patients with severe sickling phenotype
than those with mild sickling phenotype (data not shown).
Relationships Among the Biologic Markers in the Patients
with Sickle Cell Disease
Of the inflammatory markers, relationships were observed
among interleukin-6, interleukin-8, interleukin-10, interferon-c
and tumor necrosis factor-a with Pearson’s correlation coefficients
of 0.55 to 0.75 (P,0.0001). Monocyte chemoattractant protein-1
associated with interleukin-6 and interferon-c with correlation
coefficients of 0.55 and 0.56. Similarly, relationships were observed
among all three angiogenic markers, VEGF, PDGF-BB and basic
fibroblast growth factor, with Pearson’s correlation coefficients of
0.57 to 0.82. There were also relationships between the inflamma-
tory markers and angiogenic markers. Interleukin-8 and interferon-
c associated with all three angiogenic markers with correlation
coefficients of 0.50 to 0.73. Interleukin-6, interleukin-10 and tumor
necrosis factor-a associated withVEGF and fibroblast growth factor
with correlation coefficients of 0.58 to 0.78.
Relationship of Biologic Markers to Hydroxyurea Therapy
and Chronic Transfusion Program in Patients with Sickle
Cell Disease
Plasma concentrations of PDGF-BB (medians of 0.3 ng/ml
versus 0.4 ng/ml, P=0.0007) but not the other markers were
lower in 89 patients receiving hydroxyurea compared to 148
patients not receiving the medication. Plasma concentrations of
PDGF (medians of 0.8 ng/ml versus 0.3 ng/ml, P,0.0001) were
higher in 32 patients on a chronic transfusion program compared
to 201 patients not receiving chronic transfusions.
Relationship of Biologic Markers with the Hemolytic
Component, Hemoglobin Oxygen Saturation and
Hemoglobin Concentration in Patients with Sickle Cell
Disease
We recently reported independent associations of higher
hemolytic component and lower hemoglobin oxygen saturation
Biologic Markers in SCD
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patients with sickle cell disease [6]. We assessed the relationships
of the biologic markers measured in this study with the hemolytic
component, with hemoglobin oxygen saturation, and with
hemoglobin concentration. Plasma concentrations of interleu-
kin-8 correlated directly with the hemolytic component. Plasma
concentrations of interleukin-8 and fibroblast growth factor
correlated inversely with hemoglobin oxygen saturation. Plasma
concentrations of interferon-c, tumor necrosis factor-a,f i b r o b l as t
growth factor and VEGF correlated inversely with the hemo-
globin concentration (Table 2).
Bivariate Analysis of the Relationship of Biologic Markers
with Cardiopulmonary Findings in Participants with
Sickle Cell Disease (Table 3)
Interleukin 6, interleukin 8, interferon-c, tumor necrosis factor-
a, RANTES and PDGF-BB correlated positively with tricuspid
regurgitation velocity. Similar results were obtained when the
patients were stratified according to whether or not they were
being treated with hydroxyurea, although the associations were
not always statistically significant in these sub-analyses (data not
shown). None of biological markers correlated significantly with
the E/Etdi ratio by bivariate analysis.
Table 2. Bivariate relationships of biologic markers with hemolytic component and hemoglobin oxygen saturation in patients
with sickle cell disease [Pearson correlation].
Hemolytic component
(N=225)
Hemoglobin O2 saturation
(N=233)
Hemoglobin concentration
(N=237)
RP R P R P
Inflammatory markers
Interleukin-6 (pg/ml, natural log) 0.07 0.3 20.10 0.1 20.08 0.2
Interleukin-8 (pg/ml, natural log) 0.21 0.001* 20.20 0.002* 20.12 0.1
Interferon-c (pg/ml, natural log) 0.15 0.021 20.14 0.034 20.22 0.0006*
Monocyte chemoattractant protein-1 (pg/ml, natural log) 20.07 0.3 0.01 0.9 20.05 0.4
Tumor necrosis factor-a (pg/ml, natural log) 0.17 0.012 20.13 0.049 20.19 0.004*
Interleukin-10 (pg/ml, natural log) 0.15 0.026 20.18 0.006 20.14 0.021
RANTES (ng/ml, natural log) 20.03 0.7 0.04 0.6 0.17 0.007
Angiogenic markers
Fibroblast growth factor (basic) (pg/ml, sq. root) 0.15 0.022 20.19 0.004* 20.24 0.0001*
PDGF- BB (ng/ml, square root) 0.15 0.028 20.15 0.025 20.08 0.2
VEGF (pg/ml, natural log) 0.17 0.012 20.16 0.016 20.19 0.003*
*Statistically significant after adjustment for multiple comparisons.
doi:10.1371/journal.pone.0007956.t002
Table 1. Plasma concentrations of biologic markers in patients with sickle cell disease and control participants; results in median
(interquartile range).
Sickle cell disease patients (N=237) Controls (N=43) P
1
Inflammatory markers
Interleukin-6 (pg/ml) 0.8 (0.3–1.6) 0.4 (0.2–1.3) 0.031
Interleukin-8 (pg/ml) 0.4 (0.2–1.1) 0.3 (0.05–0.7) 0.001*
Interferon-c (pg/ml) 40 (16–73) 34 (11–51) 0.2
Monocyte chemoattractant protein-1 (pg/ml) 7.0 (3.7–12.9) 8.1 (2.3–12.2) 0.4
Tumor necrosis factor-a (pg/ml) 25 (6–50) 10 (2–42) 0.1
Interleukin-10 (pg/ml) 1.6 (0.4–5.7) 1.1 (0.1–2.5) 0.003*
RANTES (ng/ml) 4.0 (2.4–5.8) 6.9 (3.5–1.5) 0.0002*
Angiogenic markers
Fibroblast growth factor (basic) (pg/ml) 13.5 (3.3–32.5) 7.2 (5.1–17.0) 0.009
PDGF- BB (ng/ml) 0.4 (0.2–0.6) 0.3 (0.2–0.4) 0.043
VEGF (pg/ml) 1.6 (0.3–6.0) 0.5 (0.1–2.3) 0.002*
1From ANOVA adjusted for hydroxyurea treatment and with best transformation of the variable.
*Statistically significant after Bonferroni adjustment for multiple comparisons.
doi:10.1371/journal.pone.0007956.t001
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Cardiopulmonary Findings by Logistic Regression
Analyses in Participants with Sickle Cell Disease
There are potential relationships among the expression of
angiogenic growth factors and the inflammatory response in sickle
cell disease [37], and we observed relationships among and
between the inflammatory and angiogenic markers in this study as
described above. Furthermore, we observed associations of some
of the biologic markers measured with the hemolytic index and/or
the hemoglobin oxygen saturation (Table 2), which we previously
showed to be associated with elevated tricuspid regurgitation
velocity [6]. It was therefore important to do analyses to search for
independent relationships of biologic markers with the cardiopul-
monary findings of interest in this study.
Tricuspidregurgitationvelocity. We used logistic regression
to examine the independent relationships of biologic markers,
hemolytic component and hemoglobin oxygen saturation with
tricuspid regurgitation velocity dichotomized as $2.6 m/sec versus
,2.6 m/sec (Table 4). Greater values for PDGF-BB (P=0.009),
interleukin-6 (P=0.019) and the hemolytic component (P=0.026)
were each independently associated with increased odds of elevated
tricuspid regurgitation velocity while higher VEGF concentrations
were associated with decreased odds (P=0.005). We performed
separateanalysesinpatientswithseveresicklingphenotype and mild
sickling phenotype, and observed similar results to the overall
analysis in both subgroups. However, the relationships in the mild
sickling phenotype did not reach statistical significance because of
the small sample size.
Hemoglobin oxygen saturation did not have a significant
independent association with tricuspid regurgitation velocity after
adjustment for the hemolytic component, VEGF, PDGF and
interleukin-6 in the logistic regression model. Hydroxyurea
therapy and chronic transfusion program did not have significant
associations either.
Mitral valve E/Etdi ratio. None of the biologic markers had
a significant association with E/Etdi ratio of 9.22 or higher versus
less than 9.22.
Complex Relationship of VEGF with Other Biologic
Markers and with Tricuspid Regurgitation Velocity
Plasma VEGF concentration had significant positive relation-
ships with PDGF-BB (Figure 1a) and interleukin-6 (Figure 1b) but
not with tricuspid regurgitation velocity (Table 3) in bivariate
analyses. VEGF had a negative rather than positive independent
relationship with tricuspid regurgitation velocity in the multivar-
iate logistic regression analysis (Table 4). Figure 2a shows the
mean VEGF concentration was lower in children with tricuspid
regurgitation velocity $2.60 m/sec than those with velocity
,2.60 m/sec after adjustment for PDGF-BB, hemolytic index
and interleukin-6. In contrast, Figure 2b–d shows that the adjusted
Table 3. Bivariate relationships of biologic markers with cardiopulmonary outcomes in patients with sickle cell disease.
Tricuspid regurgitation velocity (N=218) Mitral valve E/Etdi (N=233)
RPR P
Inflammatory markers
Interleukin-6 (pg/ml, natural log) 0.20 0.004* 0.01 0.9
Interleukin-8 (pg/ml, natural log) 0.20 0.003* 0.07 0.3
Interferon-c (pg/ml, natural log) 0.24 ,0.001* 20.004 0.9
Monocyte chemoattractant protein-1 (pg/ml, natural log) 0.11 0.09 20.01 0.9
Tumor necrosis factor-a (pg/ml, nat. log) 0.22 0.001* 0.05 0.4
Interleukin-10 (pg/ml, natural log) 0.15 0.032 0.03 0.6
RANTES (ng/ml, natural log) 0.21 0.002* 20.04 0.6
Angiogenic markers
Fibroblast growth factor (basic) (pg/ml, sq. root) 0.10 0.16 0.07 0.3
PDGF- BB (ng/ml, square root) 0.20 0.003* 0.09 0.2
VEGF (pg/ml,natural log) 0.12 0.08 0.09 0.2
*Statistically significant after adjustment for multiple comparisons.
doi:10.1371/journal.pone.0007956.t003
Table 4. Independent predictors of tricuspid regurgitation velocity $2.60 m/sec by logistic regression.
Odds ratio (95% confidence interval) P
VEGF (pg/ml, natural log) 0.60 (0.42–0.86) 0.005
PDGF-BB (ng/ml, square root) 10.0 (1.77–56.29) 0.009
Interleukin-6 (pg/ml, natural log) 1.60 (1.08–2.38) 0.019
Hemolytic component (relative unit) 1.44 (1.05–1.98) 0.026
186 patients with tricuspid regurgitation velocity ,2.6 m/sec; 20 with velocity $2.6 m/sec. Variables entered into the analyses hemolytic component, hemoglobin
oxygen saturation, chronic transfusion program, hydroxyurea therapy, interleukin-6, interleukin-8, tumor necrosis factor-a, interferon-c, interleukin-10, RANTES, basic
fibroblast growth factor, PDGF-BB and VEGF.
doi:10.1371/journal.pone.0007956.t004
Biologic Markers in SCD
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higher with tricuspid regurgitation velocity $2.60 m/sec. These
observations suggest that the relationship of VEGF with tricuspid
regurgitation velocity is modified by the degree of elevation of
other angiogenic and inflammatory molecules.
Pathway Analysis of Tricuspid Regugitation Velocity in
Patients with Sickle Cell Disease (Figure 3)
The model had a good fit to the data (Chi-square=9.1, degrees
of freedom=5, P=0.11) and it was statistically significant (root
mean square error of approximation=0.05; 90% confidence
interval of 0.0 to 0.1). According to this analysis, higher hemolytic
component was a direct predictor of increasing tricuspid
regurgitation velocity (beta=0.38) and it also was associated with
lower hemoglobin concentration and higher interleukin-6 concen-
tration. Lower hemoglobin concentration was not a direct
predictor of higher regurgitation velocity, but it was associated
with higher VEGF concentration. Higher interleukin-6 concen-
tration was a direct predictor of increasing tricuspid regurgitation
velocity (beta=0.22) and it also was associated with higher VEGF
and PDGF-BB concentrations. Higher PDGF-BB concentration
was a direct predictor of increasing regurgitation velocity
(beta=0.25) while higher VEGF concentration was a direct
predictor of lower regurgitation velocity. The model predicted
22% of variation in tricuspid regurgitation velocity among
patients.
Discussion
Hemolysis and hypoxia have been identified as risk factors for
elevated tricuspid regurgitation velocity in children and adoles-
cents with sickle cell disease [6]. Here we investigated whether
markers of other biologic pathways implicated in pulmonary
hypertension in conditions other than sickle cell disease may be
associated with elevated tricuspid regurgitation velocity in sickle
cell disease as well. We also examined the relationship of these
markers to mitral valve E/Etdi, an indicator of left ventricular
diastolic function. In this process, we found that, in addition to a
composite marker of hemolysis, circulating angiogenic and
inflammatory markers were associated with elevated tricuspid
regurgitation velocity but not with elevated mitral valve E/Etdi
ratio in children and adolescents with sickle cell disease. In
multivariate analyses, higher levels of PDGF and lower levels of
VEGF were associated with elevated regurgitation velocity.
Pulmonary hypertension is characterized by abnormal prolifer-
ation of pericytes and smooth muscle cells in the pulmonary
microvasculature [38]. PDGF activates vascular smooth muscle
cells/pericytes in the process of angiogenesis [39] and promotes
the development of experimental and hypoxia-related pulmonary
hypertension by inducing the proliferation and migration of
smooth muscle cells and fibroblasts [40,41]. In the present study,
we found that greater plasma concentrations of PDGF correlated
significantly with higher values for tricuspid regurgitation velocity
in both bivariate and multivariate analyses among children and
adolescents with sickle cell disease. Other clinical and translational
studies also support a role for PDGF in promoting [40,41] the
development of pulmonary hypertension in settings other than
sickle cell disease. The pharmacologic agent, imatinib, serves as a
PDGF receptor antagonist and reverses vascular remodeling and
cor pulmonale in experimental pulmonary hypertension [42].
Recent studies indicate that PDGF receptor antagonists such as
imatinib and sunatinib are effective therapy for experimental
pulmonary hypertension [42,43], and case reports suggest that
imatinib has efficacy in human patients as well [44]. In addition,
activated platelets might be a source of increased plasma PDGF
levels in sickle cell disease [22].
In contrast to the stimulation of vascular smooth muscle cells by
PDGF, VEGF stimulates proliferation and migration of endothe-
lial cells in the process of angiogenesis [39] and has not consistently
been found to contribute to experimental pulmonary hypertension
[29,45,46]. VEGF expression is controlled by a number of
complex regulatory mechanisms [47]. Specifically during hypoxia
VEGF transcription is induced from the rapid stabilization of
hypoxia inducible factor-1 [48]. During hemolysis and subsequent
hypoxia in sickle cell disease, one would expect VEGF to be
induced, and the present data shows a strong inverse correlation of
circulating VEGF concentration with hemoglobin concentration.
Consistent with a recent study in adults [49], we did not observe a
significant relationship of plasma concentrations of VEGF with
tricuspid regurgitation velocity in bivariate analysis. However, we
found that greater VEGF concentrations were associated with
lower tricuspid regurgitation velocity in multivariate analysis. This
observation is noteworthy in the light of recent research by other
investigators indicating that PDGF and VEGF have dichotomous
roles in the regulation of vascular smooth muscle cells/pericytes:
PDGF mediates the growth of pericytes by a receptor-mediated
mechanism in a model of angiogenesis, and increased VEGF
prevents this effect of PDGF [39]. Another potential mechanism
whereby VEGF may associate with a lower regurgitation velocity
is through induction of nitric oxide: VEGF induces nitric oxide
synthesis by endothelial nitric oxide synthesis via an Akt-mediated
Figure 1. Bivariate relationships of VEGF with PDGF-BB and
interleukin-6 in patients with sickle cell disease.
doi:10.1371/journal.pone.0007956.g001
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a role for VEGF in inhibiting [29,45,46] the development of
pulmonary hypertension in settings other than sickle cell disease.
Thus, higher VEGF expression conceivably could protect from
elevation of pulmonary artery pressure in sickle cell disease by two
pathways, namely inhibition of pulmonary vascular smooth muscle
proliferation and increased production of nitric oxide by
endothelial cells.
Although we previously observed significant, independent
associations of both higher hemolytic index and lower hemoglobin
oxygen saturation with elevated tricuspid regurgitation velocity in
this cohort of children and adolescents with sickle cell disease [6],
the present study indicated that the hemoglobin oxygen saturation
was not significantly associated after adjustment for VEGF,
PDGF-BB and interleukin-6. Our findings are therefore consistent
with the possibility that effects of hypoxia on systolic pulmonary
arterial pressure are at least in part mediated by changes in
angiogenic and inflammatory responses.
Sickle cell disease is characterized by chronic low-grade
inflammation and endothelial activation [51] as manifested by
leukocytosis and monocytosis [52,53] and increased soluble
vascular cell adhesion molecules [18,54,55]. There are differing
reports regarding the involvement of cytokines as mediators of
inflammation in sickle cell disease [56,57,58,59]. In the present
study, we observed higher plasma levels of interleukin-8 and
interleukin-10 in sickle cell disease patients compared to control
subjects. Among the patients with sickle cell disease, we observed
bivariate associations of higher interleukin-6, interleukin-8,
interferon-c, tumor necrosis factor-a and RANTES concentra-
tions with higher tricuspid regurgitation velocity, and an
independent association of increased interleukin-6 concentration
with elevated tricuspid regurgitation velocity. These observations
are compatible with the possibility that pro-inflammatory
processes contribute to pulmonary hypertension in sickle cell
disease as proposed by other investigators [21] and as observed in
other settings [23,24,25,26,60]. Our observation that the relation-
ship of VEGF with tricuspid regurgitation velocity is modified by
the degree of elevation of the inflammatory marker, interleukin-6,
is paralleled by a report from the literature that pulmonary
hypertension in tumor necrosis factor-a-over-expressing mice is
associated with decreased VEGF expression [61].
There are a number of limitations to our study. Thirty-eight
percent of the patients were being treated with hydroxyurea and
13% were on a chronic transfusion program. Although plasma
concentration of PDGF was lower in the patients receiving
hydroxyurea and higher in those on a chronic transfusion
Figure 2. Adjusted mean values VEGF, PDGF-BB, interleukin-6 and hemolytic component according to tricuspid regurgitation
velocity category. Presented are least square mean (6standard error) values from ANOVA with adjustment for the other variables depicted. TRV
indicates tricuspid regurgitation velocity.
doi:10.1371/journal.pone.0007956.g002
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in examining the relationships of the biologic markers with
tricuspid regurgitation velocity or mitral valve E/Etdi. The
reliability of single echocardiographic measurements of tricuspid
regurgitation velocity and E/Etdi has not been established in
children with sickle cell disease. Other than a greater decline in
oxygen saturation during the six minute walk test in patients with
elevated tricuspid regurgitation velocity, we have not observed
functional impairment in patients with elevated tricuspid regur-
gitation velocity or mitral valve E/Etdi in children and adolescents
with sickle cell disease [6]. Other limitations to our study are that
circulating concentrations of biologic markers may not reflect the
levels to which cells of the pulmonary microvasculature are
exposed, that this was a cross-sectional rather than a longitudinal
study, and that multiple comparisons dilute the statistical
significance of individual observations. Furthermore, the negative
association of VEGF with tricuspid regurgitation velocity appears
only after adjustment for PDGF concentration. However, the
pathway analysis lends support to the finding of contrasting
associations of VEGF and PDGF with tricuspid regurgitation
velocity.
Although the clinical importance of elevated tricuspid regurgi-
tation velocity in children and adolescents with sickle cell disease
has not been clarified by long-term follow-up studies, it seems
possible that elevated velocity in this age group may identify
individuals at risk for developing pulmonary hypertension later in
life. From this standpoint, the PUSH cohort could have unique
research importance for studying the development of pulmonary
hypertension in sickle cell disease. Our observation of opposing
VEGF and PDGF profiles in normal versus elevated tricuspid
regurgitation velocity groups supports the idea that elevated
velocity associates with known factors involved in pulmonary
hypertension, and that this clinical measure may be useful for
dissecting the pathogenesis of the early stages of cardiopulmonary
complications of sickle cell disease. In general, our findings support
the idea that the etiology of pulmonary hypertension in sickle cell
disease is multi-factorial, and that pro-inflammatory and angio-
genic pathways may interact with the degree of hemolysis in
contributing to the development of pulmonary hypertension.
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